Nuclear Imaging

Molecular imaging, also called nuclear imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI.

Prediction performance of DL compared to quantitative measures and Kaplan-Meier curves for quartiles of DL. Image created by Singh et al., Cedars-Sinai Medical Center, Los Angeles, CA.

News | SPECT Imaging

Deep Learning with SPECT Accurately Predicts Major Adverse Cardiac Events

June 14, 2021 — An advanced artificial intelligence technique known as deep learning can predict major adverse cardiac ...

June 14, 2021

News | PET-CT

Canon Medical’s Digital PET/CT System Receives FDA Clearance

June 10, 2021 — Bringing the power of artificial intelligence (AI) to molecular imaging, Advanced intelligent Clear-IQ ...

June 10, 2021

The U.S. Food and Drug Administration (#FDA) approved #Aduhelm (#aducanumab) for the treatment of #Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.

News | PET Imaging

FDA Grants Accelerated Approval for Alzheimer’s Drug Aduhelm

June 7, 2021 — The U.S. Food and Drug Administration (FDA) approved Aduhelm (aducanumab) for the treatment of Alzheimer ...

June 07, 2021

Sponsored Content

Staging F-18 FDG PET/CT images of adenocarcinoma in the RUL of the lung illustrates the value of Vereos. The primary lesion in the right upper lobe appears in the upper row (PET image is left, CT image is right). A 3 mm synchronous primary or metastatic lesion in the RUL is apparent in the lower row. The precision afforded by Vereos' images provided the basis for the patient to undergo RUL lobectomy instead of thermal ablation of the primary lesion. Images courtesy of Dr. Jay Kikut and UVM

Blog | PET-CT

Digital PET Balances Scan Time and Resolution

Efficiency and effectiveness are inseparable in clinical medicine. Digital PET addresses them both. The key is the ...

October 25, 2018

Winship Cancer Institute of Emory University’s EMPIRE-1 trial is first-of-its-kind randomized patient outcomes study of amino acid PET imaging in influencing a cancer control endpoint

News | Radiation Therapy

Results Published for Axumin (Fluciclovine F 18) PET Imaging Study Demonstrating Improved Patient Outcomes in Patients with Recurrent Prostate Cancer

May 25, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

May 25, 2021

According to an open-access article in ARRS’ American Journal of Roentgenology (AJR), increased axillary lymph node or ipsilateral deltoid uptake is occasionally observed on FDG or 11C-choline PET performed after Pfizer-BioNTech or Moderna COVID-19 vaccination

News | Coronavirus (COVID-19)

Nodal and Deltoid Radiotracer Uptake on Post-COVID-19 Vaccination PET

May 19, 2021 — According to an open-access article in ARRS’ American Journal of Roentgenology (AJR), increased axillary ...

May 19, 2021

Videos | Coronavirus (COVID-19)

VIDEO: COVID Vaccine Adenopathy Can Last Up to 10 Weeks

Yael Eshet, M.D., MSc, a diagnostic radiology specialist at Sheba Medical Center in Israel, was the lead author on a ...

May 11, 2021

GE Healthcare announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa’s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18)

News | PET Imaging

GE Healthcare Acquires Zionexa

May 6, 2021 — GE Healthcare announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology ...

May 06, 2021

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by

News | PET Imaging

PET Imaging Adds Valuable Information to Brain Metastasis Monitoring

May 5, 2021 — For patients with brain metastases, amino acid positron emission tomography (PET) can provide valuable ...

May 05, 2021

The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Feature | Radiation Oncology | By Vinay Shivaprasad

The Rise of Therapeutic Radiopharmaceuticals

The term nuclear medicine is associated with the diagnostic procedures single-photon emission computed tomography (SPECT ...

May 04, 2021

Sponsored Content | Blog | Contrast Media Injectors

BLOG: Smart Injector Technology Delivers Effective and Efficient Patient Care

Technology advancements are changing consumers’ expectations, driving industries to adapt and evolve, and the healthcare ...

April 29, 2021

olecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953,113. The patent claims a quick (5 min), easy and quantitative conversion of commercially available 18F-deoxyglucose (18F-FDG) to 18F-Fluroglucaric acid (18F-FGA).

News | PET Imaging

Molecular Targeting Technologies, Inc. Announces New PET Imaging Agent

April 19, 2021 — Molecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953 ...

April 19, 2021

The inflamed joints of a #rheumatoid #arthritis patient are clearly visible in the #PET images with the novel 68Ga-DOTA-Siglec-9 #radiopharmaceutical. Image courtesy of Anne Roivainen

News | PET Imaging

Promising Results from First-in-humans Study of a Novel PET Radiopharmaceutical

April 19, 2021 — The preliminary trial results of a novel radiopharmaceutical for PET imaging of inflammation developed ...

April 19, 2021

#NorthStar Medical #Radioisotopes, LLC, a global innovator in the development, production and commercialization of #radiopharmaceuticals used for #medicalimaging and #therapeutic applications, announced a corporate update highlighting progress across its key programs during the past twelve months and upcoming milestones.

News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress

April 16, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

April 16, 2021

Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

News | Breast Imaging

Configuring Infrared Spectroscopy Tools to Better Detect Breast Cancer

April 14, 2021 — Detecting and analyzing breast cancer goes beyond the initial discovery of the cancer itself. If a ...

April 14, 2021

ScImage, Inc. celebrates its cloud partnership with Digirad Health (“Digirad”), a division of Star Equity Holdings, after a year of successful deployment of PICOM365 for mobile imaging. Digirad’s fleet of mobile SPECT, echocardiology, vascular and general ultrasound units combined with PICOM365’s cloud image management workflow leverage each company’s strengths to create an exemplary reading and reporting environment.

News | Archive Cloud Storage

ScImage Celebrates Cloud Partnership with Digirad Health

March 30, 2021 — ScImage, Inc. celebrates its cloud partnership with Digirad Health (“Digirad”), a division of Star ...

March 30, 2021

News | PET-CT

PET/CT Shows Stressed Brain Linked to Broken Heart

March 29, 2021 — Heightened activity in the brain, caused by stressful events, is linked to the risk of developing a ...

March 29, 2021

Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status

News | Radiopharmaceuticals and Tracers

Shine Medical Announces its Isotope Production Facility is Weathertight

March 26, 2021 — Shine Medical Technologies LLC announced that construction of the exterior structure of its first-of-a ...

March 26, 2021

NorthStar poised to be first commercial-scale supplier of important therapeutic radioisotopes Copper-67 (Cu-67) and Actinium-225 (Ac-225); Initial specialized SPECT imaging portfolio includes fibrin-targeted FibroScint, with potential indications in cardiovascular disease

News | SPECT Imaging

NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals

March 16, 2021 — NorthStar Medical Radioisotopes, LLC announced organizational changes to drive focused growth for its ...

March 16, 2021

The phantom used for hyperpolarized imaging, with an illustration of imaging slices acquired using the new technique. photo/©: Laurynas Dagys, University of Southampton

News | Nuclear Imaging

Hyperpolarized Proton MRI Used to Observe Metabolic Processes in Real Time

March 12, 2021 — Magnetic resonance imaging (MRI) is already widely used in medicine for diagnostic purposes ...

March 12, 2021

Diagnostic imaging studies using Tc-99m inform healthcare decisions for approximately 30 million patients annually around the world

News | Nuclear Imaging

IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Tc-99m

March 8, 2021 — IBA (Ion Beam Applications S.A., EURONEXT) and NorthStar Medical Radioisotopes, LLC, announced a ...

March 08, 2021